12 January 2023
Reponse to ASX Query Letters
30 December 2022
SPL Aware Letter
23 December 2022
Resignation of CFO / Company Secretary
23 December 2022
Starpharma receives $7.1M R&D tax incentive refund
23 December 2022
Resignation of CFO / Company Secretary
14 December 2022
Viraleze Nasal Spray Registered in Indonesia
13 December 2022
Positive AZD0466 clinical data presented by AstraZeneca
8 December 2022
Viraleze Post-Market Clinical Study in COVID-19 Patients
5 December 2022
Appendix 3Y
29 November 2022
AGM Results
29 November 2022
Retirement of non-executive director
29 November 2022
AGM Chairman’s address and CEO’s presentation
22 November 2022
Viraleze launched in Hong Kong and Macau
8 November 2022
Starpharma to present at Bell Potter Healthcare Conference
31 October 2022
Appendix 3Y
31 October 2022
Appendix 3Y
28 October 2022
2022 SPL Notice of AGM and Proxy Form
27 October 2022
Appendix 2A
27 October 2022
Appendix 2A
27 October 2022
Appendix 3G

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.